|
Jun 30
|
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
|
|
Jun 27
|
Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
|
|
May 22
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Apr 7
|
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
|
|
Apr 4
|
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
|
|
Jan 30
|
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
|
|
Jan 29
|
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
|
|
Jan 28
|
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
|
|
Jan 28
|
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
|